The overall goals of this study are to (1) expand knowledge about interactions of chlorzoxazone with alcohol by assessing the effects of chlorzoxazone compared to placebo in moderate and heavy social alcohol users and (2) to compare the effects of chlorzoxazone on visual cue induced alcohol craving to placebo in moderate to heavy social alcohol users.
The investigators propose a 45-day, double-blind, placebo-controlled crossover study in light to moderate and heavy alcohol users. The specific aims are to: 1. Determine if chlorzoxazone alters daily alcohol consumption by comparing the mean drinks consumed per day during chlorzoxazone administration compared with the mean drinks per day consumed during placebo administration. 2. To determine if polymorphisms in genes encoding for neurotransmitters or receptors involved in alcohol reward, abuse, dependence, craving, or relapse may predict the level of response to chlorzoxazone's effects on alcohol consumption or craving. 3. To investigate any change in alcohol craving during a cue induced craving task where participants view and respond to a number of images.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
48
Drug: Parafon Forte administered at study visit Other: Placebo administered at study visit
Ernest Gallo Clinic and Research Center
Emeryville, California, United States
Alcohol Consumption in Drinks/Week.
Each subject will record how many drinks/week they are consuming while on the study drug and placebo during the 45-day study. The primary outcome of this study is to determine the effect of chlorzoxazone on alcohol consumption. Reduction in alcohol consumption is measured utilizing behavioral inventories, electronic diaries, urine, and ethyl glucuronide.
Time frame: 45 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.